Bristol-Myers Squibb and GeneCentric Diagnostics announce exploratory biomarker research collaboration
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and GeneCentric Diagnostics, Inc. have announced a biomarker research collaboration to explore whether the application of GeneCentric's Cancer Subtype Platform (CSP™) might be able to identify translational biomarkers for Opdivo (nivolumab), which may help inform future clinical trials.
Novo Nordisk and Glooko partner to develop digital health solutions for people with diabetes
- Details
- Category: Novo Nordisk
Novo Nordisk and Glooko today announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The non-exclusive collaboration will combine Novo Nordisk's deep knowledge of diabetes with Glooko's digital platform and data analytics expertise.
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
- Details
- Category: Novartis
Novartis announced today a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII.
Bristol-Myers Squibb announces immunotherapy clinical collaboration with Janssen
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate the combination of Bristol-Myers Squibb's Immuno-Oncology (I-O) agent Opdivo and Janssen’s CD38-directed cytolytic antibody Darzalex in Phase 1b/2 clinical studies in multiple myeloma and solid tumors including non-small cell lung cancer, pancreatic cancer, colorectal cancer (CRC), triple negative breast cancer and head and neck cancer.
Sanofi and Boehringer Ingelheim confirm Closing of business swap
- Details
- Category: Boehringer Ingelheim
Sanofi and Boehringer Ingelheim confirmed that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi's animal health business (Merial) and Boehringer Ingelheim's consumer healthcare (CHC) business, has been successfully closed in most markets on January 1st 2017.
Top 20 World Pharma News of 2016
- Details
- Category: Business and Industry
Look back at the most prominent moments from the year 2016. We are proud to announce the 20 most popular World Pharma News from 2016, the most commonly viewed news according the collected web statistics.
Roche's emicizumab for haemophilia A meets primary endpoint in phase III study
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the primary endpoint has been met for the phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or older with haemophilia A and inhibitors to factor VIII. The study showed a statistically significant reduction in the number of bleeds over time in people treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment.
More Pharma News ...
- Bristol-Myers Squibb signs exclusive worldwide license agreement with PsiOxus Therapeutics
- Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
- Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
- Pfizer announces expansion of ASPIRE awards program for 2017 to include $5.5M in funding for breast and hematologic cancers
- Bristol-Myers Squibb strengthens capabilities with evolution of its U.S. geographic footprint
- Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
- Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer